EULARRheumatology2022Updated 2022
EULAR Recommendations for the Management of Rheumatoid Arthritis 2022
Published by European League Against Rheumatism · 58 pages · Class I–II
5Overarching Principles
11Recommendations
YesJAKi Safety Update
Summary
Free previewUpdated EULAR RA recommendations reinforce treat-to-target with DAS28 remission as primary goal. JAK inhibitors now carry updated cardiovascular and malignancy safety considerations. csDMARD monotherapy (MTX) remains first-line; biologics and JAKi added when targets not met after 3–6 months.
Rheumatoid ArthritisMTXbDMARDJAK inhibitorsTreat-to-targetDAS28
Key Recommendations
Evidence Grading & Drug Doses
What's New vs Previous Version
Implementation & Clinical Pearls
Full guideline access requires an account
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Full guideline text with all recommendations
Evidence grades (Class I/II/III, Level A/B/C)
AI-generated summary and clinical pearls
Auto-logged as CPD/CME activity
Free plan includes 10 guideline reads per day · No credit card required